[go: up one dir, main page]

PT1724284E - Proteínas de fusão com glp-1 - Google Patents

Proteínas de fusão com glp-1 Download PDF

Info

Publication number
PT1724284E
PT1724284E PT06118975T PT06118975T PT1724284E PT 1724284 E PT1724284 E PT 1724284E PT 06118975 T PT06118975 T PT 06118975T PT 06118975 T PT06118975 T PT 06118975T PT 1724284 E PT1724284 E PT 1724284E
Authority
PT
Portugal
Prior art keywords
fusion proteins
glp
proteins
glucagon
peptides
Prior art date
Application number
PT06118975T
Other languages
English (en)
Inventor
Wolfgang Glaesner
Radmila Micanovic
Tschang Sheng-Hung Rainbow
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22954069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1724284(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT1724284E publication Critical patent/PT1724284E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
PT06118975T 2000-12-07 2001-11-29 Proteínas de fusão com glp-1 PT1724284E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25195400P 2000-12-07 2000-12-07

Publications (1)

Publication Number Publication Date
PT1724284E true PT1724284E (pt) 2009-09-30

Family

ID=22954069

Family Applications (2)

Application Number Title Priority Date Filing Date
PT01995845T PT1355942E (pt) 2000-12-07 2001-11-29 Proteínas de fusão de glp-1
PT06118975T PT1724284E (pt) 2000-12-07 2001-11-29 Proteínas de fusão com glp-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT01995845T PT1355942E (pt) 2000-12-07 2001-11-29 Proteínas de fusão de glp-1

Country Status (30)

Country Link
US (1) US7271149B2 (pt)
EP (2) EP1355942B1 (pt)
JP (2) JP2004528014A (pt)
KR (2) KR20080085082A (pt)
CN (2) CN1483041A (pt)
AT (2) ATE406384T1 (pt)
AU (2) AU2689702A (pt)
BR (1) BR0116024A (pt)
CA (2) CA2716959A1 (pt)
CY (2) CY1108485T1 (pt)
CZ (2) CZ308214B6 (pt)
DE (2) DE60135581D1 (pt)
DK (2) DK1724284T3 (pt)
EA (1) EA005584B1 (pt)
EC (1) ECSP064643A (pt)
ES (2) ES2328510T3 (pt)
HK (1) HK1061411A1 (pt)
HR (1) HRP20030455A2 (pt)
HU (2) HU230603B1 (pt)
IL (3) IL155812A0 (pt)
MX (1) MXPA03005036A (pt)
NO (3) NO331273B1 (pt)
NZ (1) NZ525577A (pt)
PL (2) PL393178A1 (pt)
PT (2) PT1355942E (pt)
SI (2) SI1724284T1 (pt)
SK (2) SK288088B6 (pt)
UA (2) UA81897C2 (pt)
WO (1) WO2002046227A2 (pt)
ZA (1) ZA200303642B (pt)

Families Citing this family (333)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
WO2001079442A2 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
BR0111562A (pt) * 2000-06-16 2003-04-15 Lilly Co Eli Análogos de peptìdeo 1 semelhantes ao glucagon
EP1341902A2 (en) 2000-12-08 2003-09-10 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
US20060057651A1 (en) 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
EP1351984A2 (en) * 2000-12-13 2003-10-15 Eli Lilly And Company Amidated glucagon-like peptide-1
US7576050B2 (en) 2001-07-31 2009-08-18 The United States Of America As Represented By The Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
HUP0501192A3 (en) * 2001-08-23 2006-06-28 Lilly Co Eli Glucagon-like peptide-1 analogs
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
CN1630709A (zh) * 2001-10-18 2005-06-22 百时美施贵宝公司 人胰高血糖素样多肽－1模拟物和它们在治疗糖尿病和相关状况中的应用
PT1463751E (pt) * 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
WO2003059934A2 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
AR038102A1 (es) * 2002-01-08 2004-12-29 Lilly Co Eli Analogos extendidos de peptido 1 de tipo glucagon
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
JP4636876B2 (ja) 2002-05-24 2011-02-23 メドトロニック，インコーポレイテッド ポリペプチドの高収率生産のための方法およびｄｎａ構築物
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
CA2490409A1 (en) * 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
US20060130158A1 (en) * 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
EP1688148A1 (en) * 2002-12-03 2006-08-09 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
AU2003283216A1 (en) * 2002-12-03 2004-06-23 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
NZ541365A (en) 2002-12-27 2009-09-25 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
CA2512676A1 (en) * 2003-01-10 2004-07-29 Niigata Tlo Corporation Vector for gene therapy and method of quantifying target protein in mammal or cultured cells with the administration of the vector for gene theraphy
EP1591451A4 (en) * 2003-02-06 2009-09-02 Univ Keio peptide conjugate
WO2004093823A2 (en) * 2003-03-19 2004-11-04 Eli Lilly And Company Polyethelene glycol link glp-1 compounds
BRPI0408978B8 (pt) 2003-04-08 2021-07-27 Novo Nordisk As processos para regenerar uma fase estacionária cromatográfica
WO2004089985A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
CA2525574C (en) 2003-05-15 2015-06-30 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
CA2526169A1 (en) * 2003-06-12 2004-12-23 Eli Lilly And Company Fusion proteins
US7452966B2 (en) * 2003-06-12 2008-11-18 Eli Lilly And Company GLP-1 analog fusion proteins
CA2539253A1 (en) * 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
JP2007537981A (ja) * 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
KR101135244B1 (ko) * 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
KR20050047030A (ko) 2003-11-13 2005-05-19 한미약품 주식회사 약물의 캐리어로서 유용한 ＩｇＧ Ｆｃ 단편 및 그의제조방법
US20090238838A1 (en) * 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
DK1687019T3 (en) 2003-11-20 2018-02-12 Novo Nordisk As Propylene glycol peptide formulations that are optimal for production and use in injection devices
JP4865565B2 (ja) 2003-12-09 2012-02-01 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストを用いた食物選択の制御
MXPA06006746A (es) * 2003-12-18 2006-08-18 Novo Nordisk As Analogos de glp-1 novedosos ligados a agentes similares a albumina.
US20060252693A1 (en) * 2004-01-29 2006-11-09 Wolfgang Glaesner Glucagon-like peptide-1 analogs
CA2554089C (en) * 2004-02-09 2013-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
CN1980687B (zh) * 2004-02-09 2015-05-13 人类基因科学公司 清蛋白融合蛋白
KR20140011431A (ko) * 2004-02-11 2014-01-28 아밀린 파마슈티칼스, 엘엘씨. 선택가능한 특성을 갖는 하이브리드 폴리펩티드
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US8603969B2 (en) 2004-02-11 2013-12-10 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
WO2005097175A2 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
WO2007081302A2 (en) * 2005-03-28 2007-07-19 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
DK1759001T3 (da) 2004-04-21 2011-08-01 Enobia Pharma Inc Konjugat til tilførsel til knogler og fremgangsmåde til fremstilling deraf ved at målrette proteiner til knoglen
SI1751184T1 (sl) 2004-05-13 2010-01-29 Lilly Co Eli Fgf-21 fuzijski proteini
JP2008501765A (ja) 2004-06-11 2008-01-24 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
US8030273B2 (en) 2004-10-07 2011-10-04 Novo Nordisk A/S Protracted exendin-4 compounds
EP1799710A2 (en) 2004-10-07 2007-06-27 Novo Nordisk A/S Protracted glp-1 compounds
RU2428431C2 (ru) * 2004-12-02 2011-09-10 Домантис Лимитед Слитые конструкции лекарственного средства и конъюгаты
DE602005015257D1 (pt) * 2004-12-22 2009-08-13 Lilly Co Eli
SG158158A1 (en) * 2004-12-22 2010-01-29 Centocor Inc Glp-1 agonists, compositions, methods and uses
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
RU2007134155A (ru) * 2005-03-18 2009-04-27 Ново Нордиск А/С (DK) Glp-1 соединения с увеличенным временем полужизни
US20060280728A1 (en) * 2005-05-06 2006-12-14 Providence Health System Trimeric OX40-immunoglobulin fusion protein and methods of use
CA2608311C (en) * 2005-05-13 2012-11-27 Eli Lilly And Company Glp-1 pegylated compounds
EP1920061A4 (en) * 2005-07-27 2009-05-13 Wang Qinghua GLP / 1 / EXENDIN 4 IGG FC FUSION CONSTRUCTS FOR THE TREATMENT OF DIABETES
KR20080050576A (ko) * 2005-07-29 2008-06-09 앰프로틴 코포레이션 키메릭 치료제
WO2007016764A1 (en) * 2005-08-06 2007-02-15 Qinghua Wang Composition and method for prevention and treatment of type i diabetes
AU2006279680B2 (en) * 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
CN101296942A (zh) * 2005-08-11 2008-10-29 安米林药品公司 具有可选择特性的杂合多肽
ATE448247T1 (de) 2005-09-22 2009-11-15 Biocompatibles Uk Ltd Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
EP1942115A4 (en) * 2005-10-26 2009-03-18 Chugai Pharmaceutical Co Ltd AGGLUTINABLE GLP-1 ANALOGUE AND PROLONGED RELEASE PHARMACEUTICAL COMPOSITION
EP1965823B1 (en) * 2005-11-04 2016-05-18 Glaxosmithkline LLC Methods for administering hypoglycemic agents
WO2007053946A1 (en) * 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
CN1962695B (zh) * 2005-11-09 2011-08-31 浙江德清安平生物制药有限公司 类胰高血素肽-1融合蛋白及其制备和用途
US20080280328A1 (en) * 2005-11-18 2008-11-13 Novozymes A/S Glucoamylase Variants
US20100016547A1 (en) * 2005-11-30 2010-01-21 Takaomi Ito Glycosilated Peptide and Medicine Comprising It as an Effective Ingredient
US8293869B2 (en) 2005-12-16 2012-10-23 Nektar Therapeutics Polymer conjugates of GLP-1
US8334257B2 (en) 2005-12-20 2012-12-18 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
SG10201400426XA (en) * 2006-01-12 2014-07-30 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
WO2007092252A2 (en) * 2006-02-03 2007-08-16 Modigene Inc Long-acting polypeptides and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
CN101003574B (zh) * 2006-02-21 2010-12-15 大连帝恩生物工程有限公司 长效降血糖肽的重组表达及其在糖尿病治疗药物中的应用
MX2008013304A (es) 2006-04-20 2008-10-27 Amgen Inc Compuestos de peptido 1 tipo glucagon.
ATE444741T1 (de) 2006-05-10 2009-10-15 Biocompatibles Uk Ltd Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
EP2035450A2 (en) 2006-05-26 2009-03-18 Amylin Pharmaceuticals, Inc. Composition and methods for treatment of congestive heart failure
WO2007146038A2 (en) * 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
CA2658286A1 (en) 2006-07-18 2008-01-24 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
WO2008012629A2 (en) 2006-07-24 2008-01-31 Biorexis Pharmaceutical Corporation Exendin fusion proteins
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
WO2008025527A1 (en) * 2006-08-31 2008-03-06 F. Hoffmann-La Roche Ag Method for the production of insulin-like growth factor-i
EP2059606A4 (en) * 2006-09-06 2010-04-07 Phasebio Pharmaceuticals Inc PEPTIDE FUSION THERAPEUTIC COMPOSITIONS
TWI430806B (zh) * 2006-09-13 2014-03-21 Smithkline Beecham Corp 用於投與長效降血糖藥劑之方法
TWI428346B (zh) * 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
AU2011254001B2 (en) * 2007-01-05 2012-08-02 Covx Technologies Ireland Limited Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP1972349A1 (en) * 2007-03-21 2008-09-24 Biocompatibles UK Limited GLP-1 fusion peptides conjugated to polymer(s), their production and use
EP1975176A1 (en) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Novel glp-1 fusion peptides, their production and use
WO2008131242A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
JP5351884B2 (ja) 2007-04-23 2013-11-27 インターシア セラピューティクス，インコーポレイティド インスリン分泌促進性ペプチドの懸濁製剤及び使用
JP2009019027A (ja) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
WO2009014744A1 (en) 2007-07-25 2009-01-29 Alexion Pharmaceutical, Inc. Methods and compositions for treating autoimmune disease
JP2010535781A (ja) 2007-08-03 2010-11-25 イーライ リリー アンド カンパニー 肥満に対する処置
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
JP5606314B2 (ja) 2007-09-05 2014-10-15 ノボ・ノルデイスク・エー／エス Ａ−ｂ−ｃ−ｄ−で誘導体化されたペプチドとその治療用途
JP2010538049A (ja) 2007-09-05 2010-12-09 ノボ・ノルデイスク・エー／エス 切断型ｇｌｐ−１誘導体及びその治療的使用
BRPI0817108B8 (pt) 2007-09-21 2021-05-25 Univ California composição compreendendo uma proteína de fusão, kit compreendendo a referida composição e uso da mesma.
US20090181037A1 (en) * 2007-11-02 2009-07-16 George Heavner Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses
WO2009121804A1 (en) * 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
CN101965516A (zh) * 2008-04-03 2011-02-02 弗·哈夫曼-拉罗切有限公司 聚乙二醇化胰岛素样生长因子测定
CN101328221B (zh) * 2008-04-14 2011-03-23 中国药科大学 一种降糖多肽融合蛋白及其衍生物的结构及用途
WO2009158704A2 (en) * 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
JP5563572B2 (ja) 2008-07-23 2014-07-30 ハンミ サイエンス カンパニー リミテッド 三末端官能基を有する非ペプチド性重合体を用いた生理活性ポリペプチド薬物結合体
KR20110039348A (ko) * 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
US20100075897A1 (en) * 2008-09-23 2010-03-25 Jinan University Method for sustainedly releasing bioactive peptides and application thereof
EP2346906A4 (en) 2008-10-15 2013-04-24 Angiochem Inc CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE
EA026508B1 (ru) 2008-12-05 2017-04-28 Глэксо Груп Лимитед Единичный вариабельный домен иммуноглобулина и выделенный устойчивый к протеазе полипептид, связывающие сывороточный альбумин человека
BRPI0922689A2 (pt) 2008-12-05 2018-11-06 Angiochem Inc. conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos
DK2373681T3 (en) 2008-12-10 2017-04-24 Glaxosmithkline Llc PHARMACEUTICAL COMPOSITIONS OF ALBIGLUTID
MX2011007736A (es) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Compuestos de hormona del crecimiento estables.
CN106986933A (zh) 2009-02-11 2017-07-28 阿尔布梅迪克斯医疗公司 白蛋白变体和缀合物
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
UA98911C2 (uk) 2009-03-27 2012-06-25 Ґлаксо Ґруп Лімітед Лікувальні злиття та кон'югати інсулінотропних пептидів з доменним антитілом, що зв'язує сироватковий альбумін
BRPI1015295A2 (pt) 2009-04-20 2016-05-31 Angiochem Inc traamento de câncer de ovário usando um agente anticâncer conjugado a um análogo angiopep-2.
WO2011000095A1 (en) 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
WO2011020091A1 (en) 2009-08-14 2011-02-17 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
CN101993485B (zh) * 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
CN101993496B (zh) * 2009-08-20 2013-06-05 重庆富进生物医药有限公司 双重调节血糖血脂融合蛋白及其制法和用途
MX2012003939A (es) 2009-09-30 2012-07-30 Glaxo Group Ltd Fusiones y conjugados de farmaco.
KR101229610B1 (ko) * 2009-10-09 2013-02-05 한남대학교 산학협력단 Ｇｌｐ-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물
WO2011050052A2 (en) 2009-10-20 2011-04-28 Georgia State University Research Foundation, Inc. Protein agent for diabetes treatment and beta cell imaging
EP3421491A3 (en) 2009-10-30 2019-03-27 Albumedix Ltd Albumin variants
CN102070717B (zh) * 2009-11-19 2013-04-10 东莞太力生物工程有限公司 融合蛋白及其制备方法、编码该蛋白的dna序列、表达载体、宿主细胞、含有该蛋白的药物组合物
AU2010328305B2 (en) 2009-12-08 2015-05-14 Teva Pharmaceutical Industries Ltd. BChE albumin fusions for the treatment of cocaine abuse
CN106139158B (zh) 2010-01-22 2024-06-21 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
CA2787895A1 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Stable growth hormone compounds
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
EP2555791B1 (en) 2010-04-09 2017-11-01 Sinai Health System Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
WO2011124718A1 (en) 2010-04-09 2011-10-13 Novozymes A/S Albumin derivatives and variants
CN101875700B (zh) * 2010-04-09 2012-09-26 无锡和邦生物科技有限公司 一种增加促胰岛素分泌肽融合蛋白生物活性的方法
PH12012502018A1 (en) 2010-04-30 2018-03-21 Sanwa Kagaku Kenkyusho Co Peptide for improving biostability of bioactive substance, and bioactive substance having improved biostability
JP2013525491A (ja) 2010-05-04 2013-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 心血管障害を治療または予防し心血管保護を提供する方法
WO2011153642A1 (en) * 2010-06-10 2011-12-15 Angiochem Inc. Leptin and leptin analog conjugates and fusion proteins and uses thereof
CN101891823B (zh) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
US9234023B2 (en) * 2010-06-24 2016-01-12 Biousian Biosystems, Inc. Glucagon-like peptide-1 glycopeptides
AU2011274229A1 (en) 2010-07-02 2013-01-10 Angiochem Inc. Short and D-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
CN102311501A (zh) * 2010-07-08 2012-01-11 天津药物研究院 含有glp-1或其类似物的融合蛋白、制备方法及其应用
CN101906158B (zh) * 2010-07-14 2013-10-23 中国药科大学 一种聚乙二醇化降糖多肽及其制法和用途
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
CN102532323B (zh) * 2010-12-09 2014-07-23 天津药物研究院 一种多肽复合物、药物组合物、其制备方法和应用
PT2651398T (pt) 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
CN102533655A (zh) * 2010-12-21 2012-07-04 青岛黄海制药有限责任公司 高效表达人源重组蛋白GLP1/Fc的CHO-S细胞株及其建立方法
CA2823066A1 (en) * 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
KR20140016262A (ko) 2011-01-14 2014-02-07 레드우드 바이오사이언스 인코포레이티드 알데하이드-태깅된 면역글로불린 폴리펩타이드 및 이의 사용 방법
CN107261119A (zh) 2011-02-28 2017-10-20 独立行政法人国立循环器病研究中心 恶性肿瘤转移抑制用药物
ES2676878T3 (es) 2011-03-03 2018-07-25 Zymeworks Inc. Diseño de armazón de heteromultímero multivalente y constructos
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
CN103619175B (zh) 2011-04-12 2016-08-17 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
EP2717902B1 (en) 2011-06-06 2018-01-24 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
MX356517B (es) 2011-06-28 2018-06-01 Inhibrx Llc Polipéptidos de fusión de serpina y métodos de uso de los mismos.
CN103946388A (zh) * 2011-06-28 2014-07-23 英伊布里克斯有限责任公司 Wap结构域融合多肽及其使用方法
KR20140054009A (ko) 2011-07-01 2014-05-08 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신 융합 폴리펩타이드 및 그의 용도
MX2014000316A (es) 2011-07-08 2014-02-19 Bayer Ip Gmbh Proteinas de fusion liberadoras de relaxina y usos de las mismas.
KR20140054084A (ko) 2011-08-19 2014-05-08 도쿠리츠교세이호진 고쿠리츠쥰칸키뵤 겐큐센터 나트륨 이뇨 펩티드 수용체 gc-a 아고니스트 및 gc-b 아고니스트를 조합하여 이루어지는 악성 종양의 악화 방지용 의약
US9103841B2 (en) * 2011-08-25 2015-08-11 Lsi Medience Corporation Method for determining glucagon-like peptide-1, and kit for use in said method
ES2626013T3 (es) 2011-09-06 2017-07-21 Novo Nordisk A/S Derivados de GLP-1
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
JP2015500823A (ja) 2011-12-09 2015-01-08 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
SG11201404405UA (en) 2012-01-26 2014-08-28 Amgen Inc Growth differentiation factor 15 (gdf-15) polypeptides
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
ES2664328T3 (es) 2012-03-16 2018-04-19 Albumedix A/S Variantes de albúmina
CN107812181B (zh) 2012-03-22 2022-06-17 诺和诺德股份有限公司 Glp-1肽组合物及其制备
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
EA201491898A1 (ru) 2012-04-19 2015-08-31 Опко Байолоджикс Лтд. Варианты оксинтомодулина пролонгированного действия и способы получения указанных вариантов
IN2014DN09297A (pt) 2012-05-16 2015-07-10 Glaxo Group Ltd
WO2013172967A1 (en) 2012-05-17 2013-11-21 Extend Biosciences, Inc Carriers for improved drug delivery
US9745359B2 (en) * 2012-05-18 2017-08-29 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
AU2013271545C1 (en) 2012-06-08 2017-09-28 Mural Oncology, Inc. Ligands modified by circular permutation as agonists and antagonists
EP2863895B1 (en) 2012-06-20 2021-04-14 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
JP6498601B2 (ja) 2012-07-13 2019-04-10 ザイムワークス，インコーポレイテッド 多価ヘテロ多量体足場設計および構築物
AR094821A1 (es) * 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014072481A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
MX363326B (es) 2012-11-20 2019-03-20 Opko Biologics Ltd Metodo para incrementar el volumen hidrodinamico de polipeptidos mediante la union a peptidos carboxi-terminales de gonadotrofina.
WO2014089354A1 (en) 2012-12-07 2014-06-12 The Regents Of The University Of California Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
AR099912A1 (es) 2012-12-21 2016-08-31 Sanofi Sa Derivados de exendina-4 como agonistas dobles de glp1 / gip o triples de glp1 / gip / glucagon
EP2945703A4 (en) 2013-01-15 2016-08-31 Teva Pharma ALBU-BCHE FORMULATIONS, PREPARATION THEREOF AND USES THEREOF
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
EP2981282B1 (en) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation
WO2014194100A1 (en) 2013-05-29 2014-12-04 The Regents Of The University Of California Anti-cspg4 fusions with interferon for the treatment of malignancy
CN104277112B (zh) * 2013-07-04 2018-01-26 嘉和生物药业有限公司 长效降血糖融合蛋白
KR102616674B1 (ko) * 2013-07-31 2023-12-29 암젠 인크 성장 분화 인자 15(ｇｄｆ-15) 작제물
CN103408669B (zh) * 2013-08-01 2016-01-20 江苏泰康生物医药有限公司 Glp-1类似物融合蛋白，及其制备方法和用途
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
US20160185837A1 (en) * 2013-08-16 2016-06-30 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
WO2015054427A1 (en) 2013-10-10 2015-04-16 Beth Israel Deaconess Medical Center, Inc. Tm4sf1 binding proteins and methods of using same
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
CA2941958A1 (en) * 2013-12-10 2015-06-18 F. Hoffmann-La Roche Ag Use of the binding domain of a subunit of a multi-subunit structure for targeted delivery of pharmaceutically active entities to the multi-subunit structure
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
CA2944138C (en) * 2014-03-31 2023-06-20 Hanmi Pharm. Co., Ltd. Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
WO2015165480A1 (en) 2014-04-30 2015-11-05 Institute For Research In Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
NO2776305T3 (pt) 2014-04-23 2018-01-27
US11052132B2 (en) 2014-05-08 2021-07-06 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
CN104558198A (zh) * 2014-07-25 2015-04-29 成都贝爱特生物科技有限公司 GLP-1类似物和amylin类似物的融合蛋白制备及其用途
CN104257696B (zh) * 2014-09-04 2017-08-25 西安国誉生物科技有限公司 一种降糖稳糖酵母菌粉及其制备方法和应用
ES2685987T3 (es) 2014-09-05 2018-10-15 University Of Copenhagen Análogos de péptidos gip
JP2017536343A (ja) * 2014-10-10 2017-12-07 ノヴォ ノルディスク アー／エス 安定したｇｌｐ−１ベースのｇｌｐ−１／グルカゴン受容体コアゴニスト
CN104327187B (zh) * 2014-10-11 2018-06-08 上海兴迪金生物技术有限公司 一种重组人GLP-1-Fc融合蛋白
JP6946182B2 (ja) 2014-10-22 2021-10-06 エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ 治療用ビタミンｄコンジュゲート
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016073704A1 (en) * 2014-11-06 2016-05-12 Children's Research Institute, Children's National Medical Center Immunotherapeutics for cancer and autoimmune diseases
EP3226891A1 (en) 2014-12-05 2017-10-11 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
JP7095992B2 (ja) * 2014-12-08 2022-07-05 １グローブ バイオメディカル カンパニー， リミテッド 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用
WO2016118577A1 (en) * 2015-01-22 2016-07-28 Medimmune, Llc Thymosin-beta-four fusion proteins
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
AU2016219513B2 (en) 2015-02-09 2021-09-30 Immunoforge Co., Ltd. Methods and compositions for treating muscle disease and disorders
EP3257524B1 (en) 2015-02-11 2020-08-26 Gmax Biopharm LLC Stabilized solution preparation of pharmaceutical glp-1r antibody fusion protein
WO2016161244A2 (en) * 2015-04-01 2016-10-06 The Scripps Research Institute Methods and compositions related to gpcr agonist polypeptides
IL304950A (en) 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016205367A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
CA2989990C (en) 2015-06-19 2024-03-12 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
EP3337894A1 (en) 2015-08-17 2018-06-27 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート
WO2017041001A2 (en) 2015-09-04 2017-03-09 The California Institute For Biomedical Research Insulin immunoglobulin fusion proteins
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
CN105367664B (zh) * 2015-11-04 2019-09-20 成都贝爱特生物科技有限公司 激活GLP-1受体和Amylin受体双功能作用的融合蛋白制备及其用途
EP3964522A1 (en) * 2015-11-16 2022-03-09 Ubiprotein, Corp. A method for extending half-life of a protein
ES2882634T3 (es) 2015-11-24 2021-12-02 Transfert Plus Sec Compuestos peptídicos y conjugados con péptidos para el tratamiento del cáncer mediante quimioterapia mediada por receptores
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. METHODS OF TREATING HYPOPHOSPHATASE IN CHILDREN
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
CA3019398A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
EP3464573A4 (en) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. IMPACT OF METAL ON THE PRODUCTION OF ALKALINE PHOSPHATASES
EP3481855B1 (en) 2016-07-11 2023-09-06 OPKO Biologics Ltd. Long-acting coagulation factor vii and methods of producing same
CN106046176B (zh) 2016-08-16 2019-09-10 中国药科大学 一种高活性长效降糖融合蛋白及其制备方法与医药用途
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
CN109200273B (zh) * 2017-07-04 2021-02-19 中国药科大学 一种多肽用于制备预防或治疗脂肪肝病药物的用途
WO2018045872A1 (zh) * 2016-09-06 2018-03-15 中国药科大学 一种多肽及其用途
CN106279400A (zh) * 2016-09-06 2017-01-04 中国药科大学 P8降糖肽的设计及其用途
RU2019121992A (ru) * 2016-12-14 2021-01-15 Лигандал, Инк. Способы и композиции для доставки полезной нагрузки в виде нуклеиновых кислот и белков
CN106519016A (zh) * 2016-12-20 2017-03-22 中国药科大学 降糖调脂肽——Progly肽的设计及其用途
CN107033234B (zh) * 2017-01-03 2018-06-26 北京凯因科技股份有限公司 酰化的glp-1衍生物
US11192931B2 (en) 2017-01-25 2021-12-07 Medlmmune, Llc Relaxin fusion polypeptides and uses thereof
CA3057502A1 (en) 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
CN108727486A (zh) * 2017-04-24 2018-11-02 舒泰神（北京）生物制药股份有限公司 长效神经生长因子、制备方法及其组合物
CA3064145A1 (en) 2017-05-24 2018-11-29 Transfert Plus, S.E.C. Peptide compounds, conjugate compounds and uses thereof for treating inflammatory diseases
US11572399B2 (en) 2017-05-31 2023-02-07 University Of Copenhagen Long-acting GIP peptide analogues
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
WO2019067499A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
JP7221956B2 (ja) 2017-11-21 2023-02-14 イーライ リリー アンド カンパニー デュラグルチドを使用する方法およびデュラグルチドを含有する組成物
CN115109166A (zh) * 2017-11-24 2022-09-27 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
CN116143939A (zh) * 2017-11-24 2023-05-23 浙江道尔生物科技有限公司 一种治疗代谢疾病的多重活性蛋白
WO2019119673A1 (zh) 2017-12-19 2019-06-27 北京吉源生物科技有限公司 一种双基因修饰的干细胞及其用途
CN110028587B (zh) * 2018-01-11 2021-10-08 安源医药科技（上海）有限公司 用于调节血糖和脂质的增效型双功能蛋白
WO2019140021A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
CN110092835A (zh) * 2018-01-30 2019-08-06 上海惠盾生物技术有限公司 一种glp-1类似物-col3a1融合蛋白
SG11202006595RA (en) 2018-02-02 2020-08-28 Novo Nordisk As Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
SI3774862T1 (sl) 2018-04-05 2022-10-28 Sun Pharmaceutical Industries Limited Novi analogi GLP-1
CR20200510A (es) 2018-04-09 2020-11-26 Amgen Inc Protreínas de fusión del factor de diferenciación de crecimiento 15
WO2019200594A1 (zh) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
CN110964116A (zh) * 2018-09-26 2020-04-07 北京辅仁瑞辉生物医药研究院有限公司 GLP1-Fc融合蛋白及其缀合物
MX2021004665A (es) * 2018-10-22 2021-08-24 Janssen Pharmaceutica Nv Proteinas de fusion de peptido similar al glucagon 1 (glp1)-factor de diferenciacion de crecimiento 15 (gdf15) y usos de estas.
CA3114803A1 (en) * 2018-10-24 2020-04-30 Shire-Nps Pharmaceuticals, Inc. Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
US12187773B2 (en) 2018-12-03 2025-01-07 Antag Therapeutics Aps Modified GIP peptide analogues
WO2020118843A1 (zh) * 2018-12-12 2020-06-18 四川利通科创生物医药科技有限公司 一种glp-1突变体及其制备方法和用途
AU2019410643A1 (en) 2018-12-21 2021-08-12 Jiangsu Hengrui Medicine Co., Ltd. Bispecific protein
CA3056663C (en) 2019-04-05 2022-10-18 Jeffrey S. RIESMEYER Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
CN110151980B (zh) * 2019-06-30 2022-12-09 中国药科大学 Glp-1受体激动剂融合蛋白在制备预防或治疗高血脂药物中的应用
BR112022009938A2 (pt) 2019-11-25 2022-09-13 Alkermes Inc Compostos macrocíclicos substituídos e métodos de tratamento relacionados
EP4106727A1 (en) 2020-02-18 2022-12-28 Novo Nordisk A/S Pharmaceutical formulations
IL295797A (en) 2020-02-22 2022-10-01 Japan Chem Res Human transferrin receptor binding peptide
US12122817B2 (en) * 2020-09-22 2024-10-22 Serpentide Inc. Long-lasting GLP1 analogue drug for type-2 diabetes
CA3193453A1 (en) 2020-09-30 2022-04-07 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses
CN114685644A (zh) * 2020-12-29 2022-07-01 苏州康宁杰瑞生物科技有限公司 一种人glp-1多肽变体及其应用
JP2024506912A (ja) 2021-02-12 2024-02-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼポリペプチド及びその使用方法
TW202305012A (zh) 2021-03-22 2023-02-01 日商肽夢想股份有限公司 c-Met 蛋白質結合肽複合物
CA3214455A1 (en) 2021-03-22 2022-09-29 Peptiaid Inc Peptide and peptide-containing composition
CN113150172B (zh) * 2021-04-28 2023-09-22 中国药科大学 Glp-1r/gipr双靶点激动剂融合蛋白及其制备方法与应用
EP4355760A1 (en) 2021-06-18 2024-04-24 PeptiDream Inc. Ghr-binding pending peptide and composition comprising same
WO2023022234A1 (ja) 2021-08-19 2023-02-23 ペプチドリーム株式会社 ヒトトランスフェリンレセプター結合ペプチド
EP4389893A1 (en) 2021-08-21 2024-06-26 Takeda Pharmaceutical Company Limited Human transferrin receptor binding peptide-drug conjugate
AU2022335128A1 (en) 2021-08-24 2024-03-07 Jcr Pharmaceuticals Co., Ltd. Human transferrin receptor-binding antibody-peptide conjugate
CN118103387A (zh) 2021-09-30 2024-05-28 肽梦想株式会社 肽
CN113801853B (zh) * 2021-11-19 2022-03-15 山东兴瑞生物科技有限公司 Exendin-4融合基因修饰的MSC及其应用
CN117241821B (zh) * 2022-03-25 2024-04-09 北京质肽生物医药科技有限公司 多肽缀合物的药物组合物及其使用方法
KR20240168407A (ko) 2022-03-30 2024-11-29 페프티드림 아이엔씨. TrkB 결합 활성을 가지는 펩타이드 복합체
CN116848243B (zh) * 2022-03-30 2024-03-19 北京质肽生物医药科技有限公司 多肽缀合物的液体药物组合物和其使用方法
WO2023243120A1 (ja) 2022-06-15 2023-12-21 ペプチドリーム株式会社 ペプチド及びペプチドを含む剤
CN114774496B (zh) * 2022-06-21 2022-10-04 北京惠之衡生物科技有限公司 一种高密度发酵制备glp-1类似物的方法
AU2023287079A1 (en) 2022-06-23 2025-01-30 Guangzhou Innogen Pharmaceutical Group Co., Ltd. Fusion protein containing improved glp-1 receptor agonist and uses
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2024252336A1 (en) 2023-06-07 2024-12-12 Peptidream Inc. Peptide compositions targeting glypican-3 and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) * 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686900B1 (fr) 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
DE69522965T2 (de) * 1994-04-22 2002-04-04 Corixa Corp., Seattle Verbindungen und methoden für die stimulierungen und die erhöhung von schutzimmunantworten und il-12 herstellung
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
AR008077A1 (es) 1996-07-26 1999-12-09 Talarico Salinas Laura Beatriz Un polipeptido de fusion o una sal del mismo, su uso, un proceso para prepararlos, una composicion farmaceutica que los comprende, y un vector.
ATE493998T1 (de) 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmazeutische zusammensetzung mit einem exendin-4-peptid
RU2214419C2 (ru) * 1996-08-30 2003-10-20 Ново Нордиск А/С Glp-1 производные
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6190909B1 (en) * 1997-04-17 2001-02-20 Millennium Pharmaceuticals, Inc. TH2-specific gene
EP0887061A1 (en) * 1997-06-28 1998-12-30 The Procter & Gamble Company Faecal collector
JP2001513512A (ja) 1997-08-08 2001-09-04 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンディン作動剤化合物
ES2297902T5 (es) 1997-11-14 2013-07-09 Amylin Pharmaceuticals, Inc. Compuestos novedosos agonistas de exendina
DE69838916T2 (de) 1997-11-14 2008-12-18 Amylin Pharmaceuticals, Inc., San Diego Neuartige exendin agonisten
WO1999040788A1 (en) 1998-02-13 1999-08-19 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
DE69942306D1 (de) * 1998-02-27 2010-06-10 Novo Nordisk As Abkömmlinge von glp-1 analogen
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
JP2002504518A (ja) * 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に構造化されたミセルー様凝集体を形成する、２５％を超えるヘリックス−含有率を有するｇｌｐ−１誘導体
WO1999043707A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
CA2330527A1 (en) * 1998-06-15 1999-12-23 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
EP1137941B2 (en) * 1998-12-10 2013-09-11 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
WO2000069911A1 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting insulinotropic peptides
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
WO2001079442A2 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina

Also Published As

Publication number Publication date
IL184429A0 (en) 2007-10-31
CY1108485T1 (el) 2014-04-09
MXPA03005036A (es) 2003-09-05
WO2002046227A3 (en) 2003-04-24
CZ308214B6 (cs) 2020-03-04
CA2434237A1 (en) 2002-06-13
KR20080085082A (ko) 2008-09-22
ZA200303642B (en) 2004-08-12
ECSP064643A (es) 2009-07-25
CZ306180B6 (cs) 2016-09-14
JP2004528014A (ja) 2004-09-16
PL366208A1 (en) 2005-01-24
ES2328510T3 (es) 2009-11-13
IL184429A (en) 2010-04-15
JP2011006447A (ja) 2011-01-13
UA81897C2 (uk) 2008-02-25
EA005584B1 (ru) 2005-04-28
NO20032565L (no) 2003-08-01
ATE406384T1 (de) 2008-09-15
NO20032565D0 (no) 2003-06-05
CA2716959A1 (en) 2002-06-13
SK288088B6 (sk) 2013-06-03
EP1355942B1 (en) 2008-08-27
WO2002046227A2 (en) 2002-06-13
PT1355942E (pt) 2008-11-21
HU230603B1 (hu) 2017-03-28
EP1355942A2 (en) 2003-10-29
NZ525577A (en) 2005-05-27
CZ2014740A3 (pt) 2006-04-12
US20040053370A1 (en) 2004-03-18
HUP1300326A2 (en) 2003-10-28
AU2689702A (en) 2002-06-18
HU229218B1 (en) 2013-09-30
IL155812A (en) 2009-09-22
NO331273B1 (no) 2011-11-14
DE60139430D1 (de) 2009-09-10
US7271149B2 (en) 2007-09-18
HK1061411A1 (en) 2004-09-17
NO332221B1 (no) 2012-07-30
CN101712722A (zh) 2010-05-26
CY1109377T1 (el) 2014-07-02
CN1483041A (zh) 2004-03-17
UA93662C2 (uk) 2011-03-10
CA2434237C (en) 2012-05-15
AU2002226897B2 (en) 2007-10-25
DK1724284T3 (da) 2009-11-02
ES2311560T3 (es) 2009-02-16
HRP20030455A2 (en) 2004-08-31
SI1724284T1 (sl) 2009-12-31
CZ20031602A3 (cs) 2006-04-12
SK6702003A3 (en) 2004-08-03
KR20040038901A (ko) 2004-05-08
SK288342B6 (en) 2016-03-01
NO20101602L (no) 2003-08-01
NO20111369L (no) 2003-08-01
EA200300644A1 (ru) 2003-12-25
DE60135581D1 (de) 2008-10-09
DK1355942T3 (da) 2008-11-17
PL393178A1 (pl) 2011-02-14
SI1355942T1 (sl) 2009-02-28
IL155812A0 (en) 2003-12-23
EP1724284A3 (en) 2007-04-18
EP1724284B1 (en) 2009-07-29
HUP0302529A3 (en) 2009-03-30
KR100942864B1 (ko) 2010-02-17
PL209550B1 (pl) 2011-09-30
ATE437891T1 (de) 2009-08-15
HUP0302529A2 (hu) 2003-10-28
EP1724284A2 (en) 2006-11-22
BR0116024A (pt) 2005-12-13

Similar Documents

Publication Publication Date Title
AU2689702A (en) Glp-1 fusion proteins
WO2003058203A3 (en) Extended glucagon-like peptide-1 analogs
AU2002322403A1 (en) Glucagon-like peptide-1 analogs
WO2001098331A3 (en) Glucagon-like peptide-1 analogs
PL366826A1 (en) Reducing the immunogenicity of fusion proteins
WO2003011892A3 (en) Glp-1 exendin-4 peptide analogs and uses thereof
SI1095140T1 (sl) Nevrotrofični dejavniki
HK1120556A1 (en) Neurotrophic factors
WO2001080871A3 (de) Anwendung von guanylat-zyklase-c (gc-c) agonisten als insulinotrope faktoren zur behandlung von diabetes mellitus typ 2
MXPA01011719A (es) Una composicion de somatotropina con inyectabilidad mejorada.
UA88862C2 (en) Glucagon-like peptide-1 analogs